Genentech, Inc. Release: Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival in Advanced Breast Cancer

ORLANDO, Fla.--(BUSINESS WIRE)--Genentech, Inc. today announced results of a Phase III study (RIBBON 1) that showed Avastin® (bevacizumab) plus commonly used chemotherapies, including capecitabine and anthracycline-based therapies, increased the time women receiving first-line therapy for advanced HER2-negative breast cancer lived without the disease worsening (progression-free survival or PFS), compared to the chemotherapies alone. The safety profile of Avastin was consistent with previous experience, and no new safety signals for Avastin were observed in the study. The data will be presented on June 1, 2009, during the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida.